Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are studying WIN378, a long-acting medicine, in adults with moderate to severe chronic obstructive pulmonary disease COPD. WIN378 targets a protein called TSLP that causes lung inflammation and may influence COPD symptoms and control. This Phase 2a trial aims to find the right dose by assessing safety, how the body processes the medicine, and its effects on markers of inflammation, lung function, and disease control. Participants will receive subcutaneous injections of WIN378 at different doses or a placebo over a 24-week treatment period while continuing their usual COPD therapies. The study is randomized, double-blind, and placebo-controlled, ensuring a thorough comparison of effects. The treatment phase lasts 24 weeks, followed by monitoring up to 36 weeks for safety and drug concentration in the blood. During the study, participants will undergo lung function tests, blood tests, and exhaled breath analyses to assess inflammation and COPD control. Researchers will monitor vital signs, laboratory parameters, and any adverse events throughout the 36-week period. The trial also tracks the presence of antibodies against WIN378. Participants are involved in regular evaluations to help understand how the medicine works and its safety profile.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and pharmacokinetics of INM004 in children with Hemolytic Uremic Syndrome caused by Shiga toxin-producing Escherichia coli STEC-HUS. This study aims to assess how well INM004, when added to standard care, improves kidney function and reduces complications, mortality, and hospital stay in affected pediatric patients. Participants will be randomly assigned to receive either two doses of INM004, an Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin fragment, or two doses of a placebo solution. Each dose is given intravenously 24 hours apart, with infusion times adjusted based on body mass index. The study includes a 28-day acute phase and further assessments up to 90 days to monitor recovery and other health outcomes. During the study, children will undergo evaluations of kidney function, blood tests for markers of disease activity, and safety assessments. Researchers will measure the time to kidney function recovery as the primary outcome, along with mortality rates, dialysis needs, and hospital stay length. The trial lasts for at least 90 days, including close monitoring of health status and medication effects throughout this period.
Actively Recruiting
Researchers are investigating whether a new management strategy for hypertension that combines usual care visits with the use of the ESH CARE App improves blood pressure control and related health outcomes compared to standard care. This one-year, randomized study aims to assess differences in office, home, and ambulatory blood pressure control, as well as cardiovascular and kidney-related measures in patients with uncontrolled hypertension. Participants are randomly assigned to one of two groups the usual care group, which receives standard three-monthly visits with therapy adjusted based on office blood pressure, and the POST-strategy group, which adds use of the ESH CARE App to communicate home blood pressure readings to a referral center. In the POST group, therapy adjustments occur every 15 days based on home measurements. Both groups undergo regular visits at baseline, three, six, and twelve months with clinical assessments, blood tests, urine tests, echocardiograms, ECGs, and ambulatory blood pressure monitoring. Throughout the study, participants measure home blood pressure regularly, with the POST group measuring twice weekly plus seven consecutive days before visits, and the usual care group measuring before baseline and study end. Researchers monitor blood pressure changes, heart structure, kidney function, and medication use to evaluate the effects of each strategy. The total participation lasts about one year, with detailed clinical and laboratory evaluations at scheduled intervals to assess treatment impact and safety.
Actively Recruiting
Researchers are investigating the effectiveness of initial triple combination therapy versus initial double oral therapy in adults with pulmonary arterial hypertension PAH who are either intermediate-high risk or intermediate-low risk with severe hemodynamic impairment. This phase IV, randomized, open-label trial aims to optimize treatment strategies for PAH by comparing the proportion of patients achieving low-risk status between the two treatments. The study focuses on patients with idiopathic, hereditary, drug-induced, connective tissue disease-associated, or corrected congenital heart disease-related PAH. Participants are randomly assigned to one of two groups one receives double oral therapy consisting of an endothelin receptor antagonist ERA and a phosphodiesterase type-5 inhibitor PDE-5i, while the other group receives initial triple therapy that includes the same double oral combination plus parenteral treprostinil administered subcutaneously or intravenously via an infusion pump. All medications start within three weeks of randomization, and patients in the treprostinil group receive training on pump use and medication management. Dose adjustments of treprostinil are made to reach a target or maximum tolerated dose over 24 weeks and beyond. Participants will be followed for 12 to 48 weeks with up to 10 visits, including phone calls and in-person assessments. The study evaluates risk status using a standardized four-strata risk-assessment tool, hemodynamic parameters via right heart catheterization, echocardiogram measures, and patient-reported outcomes such as quality of life and symptom questionnaires. Safety is monitored through routine care without additional invasive procedures beyond standard PAH management. The primary outcome is the achievement of low-risk status between weeks 12 and 48, with secondary outcomes assessing heart function, clinical worsening, survival, and quality of life changes.
1-10 of 14
1